gliclazide has been researched along with Cardiovascular Stroke in 14 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| "We conducted a population-based cohort study of patients aged 66 years and older who were hospitalized for acute myocardial infarction or who underwent percutaneous coronary intervention between 1 April 2007 and 31 March 2010 while receiving either glyburide or gliclazide." | 3.78 | Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. ( Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR, 2012) |
| "In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality." | 2.79 | The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
| "The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | 2.42 | Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
| "Gliclazide or saline was given q12 h for 48 h to rats received isoprenaline." | 1.38 | Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats. ( Bao, Y; Shuyuan, L; Sun, X; Yang, W; Yerong, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, EH | 1 |
| Han, K | 1 |
| Kim, B | 1 |
| Lee, DH | 1 |
| Douros, A | 1 |
| Yin, H | 1 |
| Yu, OHY | 1 |
| Filion, KB | 1 |
| Azoulay, L | 1 |
| Suissa, S | 1 |
| Blomster, JI | 1 |
| Zoungas, S | 3 |
| Chalmers, J | 3 |
| Li, Q | 2 |
| Chow, CK | 1 |
| Woodward, M | 3 |
| Mancia, G | 2 |
| Poulter, N | 2 |
| Williams, B | 1 |
| Harrap, S | 2 |
| Neal, B | 2 |
| Patel, A | 3 |
| Hillis, GS | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Mohammedi, K | 1 |
| Marre, M | 1 |
| Argaud, L | 1 |
| Garrier, O | 1 |
| Loufouat, J | 1 |
| Gomez, L | 1 |
| Couture-Lepetit, E | 1 |
| Gateau-Roesch, O | 1 |
| Robert, D | 1 |
| Ovize, M | 1 |
| de Galan, BE | 1 |
| Anderson, C | 1 |
| Dufouil, C | 1 |
| Pillai, A | 1 |
| Cooper, M | 1 |
| Grobbee, DE | 1 |
| Hackett, M | 1 |
| Hamet, P | 1 |
| Heller, SR | 1 |
| Lisheng, L | 1 |
| MacMahon, S | 1 |
| Pan, CY | 1 |
| Travert, F | 1 |
| Kristiansen, SB | 1 |
| Løfgren, B | 1 |
| Nielsen, JM | 1 |
| Støttrup, NB | 1 |
| Buhl, ES | 1 |
| Nielsen-Kudsk, JE | 1 |
| Nielsen, TT | 1 |
| Rungby, J | 1 |
| Flyvbjerg, A | 1 |
| Bøtker, HE | 1 |
| Bao, Y | 1 |
| Sun, X | 1 |
| Yerong, Y | 1 |
| Shuyuan, L | 1 |
| Yang, W | 1 |
| Juurlink, DN | 1 |
| Gomes, T | 1 |
| Shah, BR | 1 |
| Mamdani, MM | 1 |
| Maddock, HL | 1 |
| Siedlecka, SM | 1 |
| Yellon, DM | 1 |
| Belcher, G | 1 |
| Lambert, C | 1 |
| Goh, KL | 1 |
| Edwards, G | 1 |
| Valbuena, M | 1 |
| Davis, TM | 1 |
| Parsons, RW | 1 |
| Broadhurst, RJ | 1 |
| Hobbs, MS | 1 |
| Jamrozik, K | 1 |
| Ballagi-Pordány, G | 1 |
| Köszeghy, A | 1 |
| Koltai, MZ | 1 |
| Aranyi, Z | 1 |
| Pogátsa, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gliclazide and Cardiovascular Stroke
| Article | Year |
|---|---|
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl | 2004 |
2 trials available for gliclazide and Cardiovascular Stroke
| Article | Year |
|---|---|
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2014 |
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea | 2016 |
11 other studies available for gliclazide and Cardiovascular Stroke
| Article | Year |
|---|---|
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent | 2020 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction.
Topics: Animals; Calcium; Gliclazide; Glyburide; Hemodynamics; Male; Mitochondria; Myocardial Infarction; Ni | 2009 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A | 2009 |
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Glycogen; Lactic Acid; Male; Myocardial I | 2011 |
Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Size; Gene Expression Regulation; Gliclazide; Heart | 2012 |
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2012 |
Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide.
Topics: Animals; Anti-Arrhythmia Agents; Gliclazide; Glyburide; Hypoglycemic Agents; Ischemic Preconditionin | 2004 |
Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment.
Topics: Adult; Arrhythmias, Cardiac; Diabetes Complications; Diabetes Mellitus; Digitalis Glycosides; Diuret | 1998 |
Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.
Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Carbutamide; Dose-Response Relationship, Drug; Electro | 1990 |